Cel-Sci Stock Shows Market Leadership With Jump To 81 RS Rating

Cel-Sci (CVM) saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 78 to 81.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock’s price performance over the trailing 52 weeks matches up against that of all other stocks.

Decades of market research reveals that the top-performing stocks tend to have an RS Rating of over 80 in the early stages of their moves.

See How IBD Helps You Make More Money In Stocks

Cel-Sci stock is now considered extended and out of buy range after clearing an 18.10 buy point in a third-stage consolidation back in January. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips. Also, check out “Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks.”


The biotech firm posted -12% earnings growth in its most recent report, while sales growth came in at -100%.

The company holds the No. 186 rank among its peers in the Medical-Biomed/Biotech industry group. Biontech Se Ads (BNTX) and Vanda Pharmaceuticals (VNDA) are also among the group’s highest-rated stocks.  For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks


Most Related Links :
todayuknews Governmental News Finance News

Source link

Back to top button
Native News Post